BG Medicine, Inc. BGMD
At closeNov 2, 2026, 4:00 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 1.14K
- Revenue (ttm)
- 1.57M
- Shares out
- 11.37M
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 450
- Avg volume
- 278
- Open
- 0.0001
- Previous close
- 0.0001
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.0001 – 0.0001
- Beta
- 1.55
- Analysts
- Hold
- Price target
- 1.40 (+1399900.0%)
- Earnings date
- Apr 4, 2016
2Y 0.0000 (0.00%)
Key statistics
- Enterprise value
- -619.44K
- PEG ratio
- 0.00
- Price / sales
- 0.34
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -47.70%
- Free cash flow
- -2.11M
- Total cash
- 1.52M
- Total debt
- 0
- Return on equity
- -902.64%
- Short % of float
- 10.14%
- 50-day average
- 0.115143
- 200-day average
- 0.124464
Analyst view
Consensus: hold
Next earnings
Apr 4, 2016
Expected Apr 4, 2016. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Apr 4, 2016 | Dec 1, 2015 | 0.00 | — | — | — |
| Nov 17, 2015 | Sep 1, 2015 | 0.00 | -0.27 | — | — |
| Aug 14, 2015 | Jun 1, 2015 | 0.00 | -0.23 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 8, 2013 | Robert W. Baird | down | Outperform | Neutral |
| Aug 30, 2012 | Mizuho | init | — | Buy |
| Mar 15, 2011 | Robert W. Baird | init | — | Outperform |
About BG Medicine, Inc.
BG Medicine, Inc. engages in development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Laboratories & Research
- Country
- United States
- Website
- bg-medicine.com
News
Progyny (NASDAQ:PGNY) versus BG Medicine (OTCMKTS:BGMD) Head-To-Head Contrast 
Critical Comparison: BG Medicine (OTCMKTS:BGMD) and Alignment Healthcare (NASDAQ:ALHC) 
Ardent Health (NYSE:ARDT) vs. BG Medicine (OTCMKTS:BGMD) Head-To-Head Comparison 
Earnings Scheduled For March 31, 2015 
Earnings Scheduled For August 14, 2014 
Morning Market Movers - Earnings Scheduled For March 13, 2013
Your note
Sign in to keep a note on BGMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADOURIAN ARAM S. | Officer | Disposition (Non Open Market) | Mar 30, 2016 | 35,770 |
| AFEYAN NOUBAR | Director | Sale | Dec 8, 2015 | 0 |
| FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC | Beneficial Owner (10% or more) | Ownership Statement | Jul 13, 2015 | 0 |
| HALL STEPHEN P | Officer | Disposition (Non Open Market) | Mar 30, 2016 | 31,034 |
| SEAWELL HAYGOOD PATERSON SR | Other | Ownership Statement | May 4, 2016 | 1,288,965 |
| SOHMER PAUL R | Officer | Disposition (Non Open Market) | Mar 30, 2016 | 53,161 |